Sahlgrenska University Hospital-Vastra Gotalandsregionen
- Address
- Bla Straket 5, 413 46 Gothenburg, Sweden
Urology and Male Urogenital Diseases
At Sahlgrenska University Hospital-Vastra Gotalandsregionen in Gothenburg, clinical research in urology focuses strongly on prostate cancer and urothelial cancer, with studies also addressing biochemical recurrence after surgery and advanced disease. These trials are designed to improve treatment effectiveness, refine imaging-guided care, and support better long-term cancer control.
- Prostate cancer and biochemical recurrence after surgery
- Urothelial cancer and other genitourinary malignancies
- Testing treatment strategies that may improve survival and reduce recurrence
The site’s urology program reflects a broad interest in both localized and advanced genitourinary cancers, combining patient-centered care with research aimed at more precise and effective treatment choices.
Neoplasms and Oncology Research
A major part of the research portfolio at this hospital involves cancer studies across several therapeutic areas, including breast cancer, melanoma, lung cancer, pancreatic cancer, and colorectal cancer. The trials are largely focused on evaluating new therapies, comparing treatment combinations, and improving outcomes for patients with advanced or high-risk disease.
- Advanced solid tumors and metastatic cancer
- Breast, melanoma, lung, pancreatic, and colon cancers
- Assessing new immunotherapy and targeted treatment approaches
This oncology activity highlights a strong commitment to improving survival, disease control, and personalized treatment selection for people with a wide range of malignant tumors.
Cardiovascular Diseases and Stroke Prevention
The site is also active in cardiovascular research, with studies in atrial fibrillation, heart failure, Takotsubo syndrome, and pulmonary arterial hypertension. Several trials aim to prevent stroke and systemic embolism, improve rhythm control, and evaluate treatments that may reduce hospitalizations and other serious complications.
- Atrial fibrillation and stroke prevention
- Heart failure and pulmonary arterial hypertension
- Testing therapies to improve cardiovascular outcomes and safety
These studies show a clear emphasis on both common and complex heart and vascular disorders, with research designed to support safer and more effective long-term management.
Respiratory Tract Diseases and Chronic Obstructive Pulmonary Disease
In the field of respiratory medicine, trials at this site include COPD, cystic fibrosis, and pulmonary fibrosis-related conditions. The research is aimed at easing symptoms, lowering exacerbation rates, and improving lung function and overall quality of life for people living with chronic respiratory illness.
- Chronic obstructive pulmonary disease and frequent exacerbations
- Cystic fibrosis and rare mutation-related disease
- Evaluating treatments that may improve breathing and disease stability
This work reflects ongoing efforts to advance care for chronic lung diseases through better symptom control and more durable treatment benefit.
Nervous System Diseases and Mental Disorders
Research in neurology and psychiatry includes studies in acute ischemic stroke, epilepsy, Parkinson’s disease, multiple sclerosis, and major depressive disorder. The main goals are to improve recovery after neurologic events, slow disease progression, and test new options for mood-related conditions, including cancer-related depression.
- Stroke recovery and stroke prevention
- Epilepsy, Parkinson’s disease, and multiple sclerosis
- Evaluating new treatments for neurologic and psychiatric conditions
This broad portfolio shows active investigation into both brain disorders and mental health, with a focus on practical improvements in daily functioning and long-term outcomes.
Immune System Diseases and Inflammatory Conditions
The site also conducts trials in immune-mediated diseases such as atopic dermatitis, Sjögren’s syndrome, and systemic sclerosis. These studies are intended to assess whether new therapies can better control inflammation, reduce symptoms, and improve patient comfort in chronic autoimmune and skin conditions.
- Atopic dermatitis and other inflammatory skin disease
- Sjögren’s syndrome and systemic sclerosis
- Testing therapies that may improve immune-related disease control
This area of research supports a wider effort to improve care for autoimmune disorders that can affect the skin, glands, and connective tissues.
Female Urogenital Diseases and Reproductive Health
Clinical trials in this area include studies of ectopic pregnancy, preeclampsia, and labour induction. The research is focused on improving maternal and pregnancy outcomes, while also exploring safer and more effective ways to manage common obstetric complications.
- Ectopic pregnancy and treatment options
- Preeclampsia and pregnancy prolongation strategies
- Evaluating safer approaches to labour induction
These studies show that the site contributes not only to urologic research but also to important women’s health questions in reproductive medicine.
Hemic and Lymphatic Diseases
The research portfolio includes studies in myelodysplastic syndrome, multiple myeloma, chronic lymphocytic leukemia, and lymphoma. These trials are generally aimed at improving disease control, reducing transfusion needs, and finding better treatment options for blood cancers and related disorders.
- Myelodysplastic syndrome and anemia management
- Multiple myeloma, lymphoma, and chronic lymphocytic leukemia
- Testing therapies to improve blood cancer outcomes and supportive care
This work adds another important dimension to the site’s broader oncology and hematology activity.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 14 therapeutic areas and 15 of 122 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 121 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 25 by active trials.
- 1Vaestra Goetalandsregionen4active
lock +24 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC6trials
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Sahlgrenska University Hospital-Vastra Gotalandsregionen
lock Showing 1 of 61 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 122 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 6 | Unknown | 2018-08-24 | 2025-12-19 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
